NewLimit
PrivateLast Round
Series C
Jun 2, 2026
Est. Valuation
$3.1B
Total Funding Raised
$760M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
NewLimit is a biotechnology company that develops epigenetic reprogramming therapies to reverse the aging process and extend human healthspan.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NewLimit Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
NewLimit Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 2, 2026 | ||||
| Convertible Debt | Oct 20, 2025 | ||||
| Series B | May 6, 2025 | ||||
| Series A | May 16, 2023 |
NewLimit Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series C, Convertible Debt, Series B |
| S32 | Convertible Debt |
| Duke University Management Company | Convertible Debt |
| Greenoaks Capital Partners | Series C |
| Khosla Ventures | Series C, Series B |
| Pathfinder Venture Capital | Series B, Series C, Series A |
| Thrive Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
$435M round led by Founders Fund.
- Jan 1, 2026
Active program targets vascular endothelial integrity in aged and diseased patients.
NewLimit Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NewLimit's valuation, stock price, and market status.